secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001558370-22-012165
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q2 revenue $123.5M record, raises FY Adj EBITDA guidance to $245-255M
-------------------------------------------------------------------------------

- Q2 net product revenue $123.5M (record), up from $82.9M YoY.
- GAAP net loss $5.2M ($0.15 loss per share) vs $72.8M income in prior year (included tax benefit).
- Adjusted EBITDA $71.2M, up from $40.1M YoY; full-year Adj EBITDA guidance raised to $245-255M.
- BDSI integration complete; on track to exceed targeted run-rate synergies of at least $75M.
- Opioid lawsuits resolved via master settlement agreement covering 27 pending cases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/0001558370-22-012165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837022012165/coll-20220804x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-22-012165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer